Tarsus Pharmaceuticals, Inc. TARS Accrued liabilities
Accrued liabilities at other companies
Other financials
Where this comes from
Reported directly by Tarsus Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:IncreaseDecreaseInOtherAccruedLiabilities.
The official record: Tarsus Pharmaceuticals, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Tarsus Pharmaceuticals, Inc.'s accrued liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Tarsus Pharmaceuticals, Inc.'s accrued liabilities?
- Tarsus Pharmaceuticals, Inc. (TARS) reported accrued liabilities of $15.46M in Q1 2026.
- How has Tarsus Pharmaceuticals, Inc.'s accrued liabilities changed year-over-year?
- Tarsus Pharmaceuticals, Inc.'s accrued liabilities increased by 52.1% year-over-year, from $10.17M to $15.46M.